Business Context and Reporting Period
Cytosorbents Corp (CTS) filed a Form 8-K on July 9, 2019, reporting the entry into a material definitive agreement. The company is incorporated in Delaware and trades on the Nasdaq Capital Market.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a new securities offering agreement.
Material Changes
On July 9, 2019, the Company entered into an Open Market Sale Agreement with Jefferies LLC and B. Riley FBR, Inc. Key terms include:
- Offering Size: Up to $25,000,000 of common stock.
- Method: "At the market" offerings, block transactions, or privately negotiated transactions.
- Commission: Agents will receive up to 3.0% of gross proceeds.
- Registration: Shares will be issued under an existing effective Form S-3 registration statement (File No. 333-226372).
Guidance, Outlook, and Risks
The filing states that the Company cannot provide assurances that it will issue any shares pursuant to the agreement. The offering will terminate upon the sale of the maximum amount or earlier termination by the parties. No specific financial guidance or operational outlook is provided in this report.
Investor Verification Checklist
- Verify the current market price of CTSO shares to assess potential dilution impact.
- Review the full text of the Open Market Sale Agreement (Exhibit 1.1) for specific pricing parameters or conditions.
- Check subsequent filings to determine if and when shares were actually sold under this agreement.
- Confirm the status of the underlying Form S-3 registration statement.